



**UNIVERSITY OF LEICESTER
&
UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST
JOINT RESEARCH & DEVELOPMENT SUPPORT OFFICE
STANDARD OPERATING PROCEDURES**

**University of Leicester (UoL) Research Governance Office
SOP S-1033 UoL**

**Process for Assessing Site Feasibility for
Research Sponsored by the University of Leicester (UoL)**

Version 4.1, September 2021

OFFICE BASE

Research Governance Office
Academic Department, Ground Floor
Leicester General Hospital
Gwendolen Road
Leicester
LE5 4PW

Effective Date: October 2021



1. INTRODUCTION

This Standard Operating Procedure (SOP) defines the procedure to be used when identifying sites to undertake research sponsored by the UoL. It is essential that a feasibility assessment is undertaken by each site (including when there is only one site i.e. only UHL) to ensure that they are able to conduct the research in accordance with the requirements of the protocol, and will be able to deliver the recruitment and achieve the national time and target deadlines.

2. SCOPE

This SOP applies to all research sponsored by the University of Leicester. It must be used for both single and multi-site research.

3. DEFINITION

A feasibility assessment is designed to identify whether a site is able to deliver a study protocol with or without modification to organisational process. Feasibility is a process of comprehensive assessment, including risk assessment and contingency planning. Conducting a thorough feasibility assessment increases the potential for swift study approvals, and limits operational delays, therefore allowing a smooth transition from Sponsor Green Light for each site, first patient recruited within national targets, and delivery of study.

A comprehensive feasibility assessment can identify problems needing to be addressed that an adverse effect on the sites ability to deliver to the protocol. It helps to identify at an early stage where issues are insurmountable and therefore excludes the site from being able to participate. This enables resource to be targeted more appropriately to enable sites that can deliver, to deliver.

4. PROCESS

4.1 All studies

Investigators wishing to undertake research that is sponsored by the UoL must contact the Research Governance Office at the earliest opportunity to discuss the process for site selection. The Sponsor application and risk assessment process includes a requirement that each site selected (after 1st April 2014) to host the research has completed a Site Feasibility Assessment (SFA) - Appendix 1. SFA(s) will be reviewed and discussed as part of the Sponsor Green Light Process. A site without a completed SFA will not receive authorisation to be added as a site from the Sponsor.

The SFA allows sites to make a real time assessment about their feasibility status. There are three options to choose:

- Feasible – no future action required
- Potentially feasible – areas to be addressed / resolved
- Not feasible at this time

It is expected that the Chief Investigator (CI) will delegate an appropriate individual to manage the SFA process, and collate all responses from sites to send to the Sponsor.

The SFA includes information about all support services within the sites, R&D / R&I Offices, contracts contacts and the clinical team. It is expected that an individual within the site be identified to complete the SFA on behalf of the site. This does not necessarily need to be the Principal Investigator (PI) but should be an individual with appropriate organisational knowledge.

It is recognised that there will be sections of the SFA that are not relevant to every study. In these cases, it must be made clear that the protocol does not require these sections to be completed.

When completed, the SFA must be sent to the Research Governance Manager or delegate for review. The assessment will be discussed with the CI and a decision made about whether or not it is appropriate or feasible for the individual site to be included in the study. This decision will be communicated by email from the Sponsor to the PI, copied to the CI and site R&I/ R&D Office.

A copy of the email and the completed SFA must be retained in the site's Investigator Site File, the CI's Trial Master File within the individual site section, and the Sponsor file.

4.2 Studies using Investigational Medicinal Products (IMP)

In addition to the SFA, where a study requires the use of Investigational Medicinal Products (IMP), the Pharmacy Feasibility Assessment – Appendix 2 must also be completed by the Pharmacy at the site.

It is essential that this document be completed by a suitably qualified individual within the Pharmacy department at the site. Evidence of appropriateness and qualification of the individual completing the form will be required by the Sponsor. This evidence can be in the form of a CV attached to the completed Pharmacy Feasibility Assessment.

5. NON-COMPLIANCE

The aims of undertaking a feasibility assessment are to review recruitment and retention strategies, assess the sites facilities, review availability of resources; staffing, support departments, ethics and R&D / R&I approval processes and contracts and budget requirements. The burden for meeting recruitment and retention commitments are the responsibility of the investigators but also weigh heavily on the Sponsor to ensure they select sites that they think will meet the protocol requirements.

Unmet recruitment and retention targets are costly for the Sponsor but also for the sites if they plough lots of resources into setting up a study, only to find there are insufficient patient numbers.

There will be an automatic critical finding if it is found that a site has been added to a study without evidence of the SFA process, post 1st April 2014. The Sponsor SOP S-1016 UoL will be followed. It is likely that the study will be suspended at all sites while an investigation is carried out.

6. RESPONSIBILITIES

| Responsibility Undertaken by | | Activity | |
|------------------------------|--------------------|--------------------------------------|--|
| 1 | Chief Investigator | Chief Investigator | Delegate an appropriate individual to undertake the SFA process |
| 2 | Chief Investigator | Chief Investigator or their delegate | Communicate with the Sponsor and provide copies of completed SFAs. |

| Responsibility Undertaken by | | Activity | |
|------------------------------|---------|---|---|
| 3 | Sponsor | Research Governance Manager or delegate | Complete Sponsor Risk Assessment /Sponsor review and review of SFA. Liaise with CI and record discussion about inclusion of individual sites. |
| 4 | Sponsor | Research Governance Manager or delegate | Confirm in writing to the PI at individual site outcome of SFA decision. |
| 5 | Sponsor | Research Governance Manager or delegate | Manage the Pharmacy Feasibility document and confirm appropriateness of individual completing |

This table is used to track the development and approval of the document and any changes made on revised / reviewed versions

Development and approval Record for this document

| | |
|-----------------------------|---|
| Author/Lead Officer: | Cat Taylor |
| Job Title: | Head of Research Assurance |
| Reviewed by: | Research Sponsorship Management and Operations Group |
| Approved by: | Professor Nigel Brunskill  |
| Date Approved: | 13/10/2021 |

Review Record

| Date | Issue Number | Reviewed By | Description Of Changes (If Any) |
|------------|--------------|-----------------|---|
| April 2015 | 2 | RSMOG | Minor administrative changes to text and footer, change to logos, addition of Loughborough University to front page |
| May 2016 | 3 | RSMOG | Minor changes to Appendix 1 to add signature field and amendment in 4.1 to state email not letter. |
| Nov 2016 | 4 | Diane Delahooke | Change of address, changed logo in appendices, consistency checks with UHL. |
| Sept 2021 | 4.1 | Cat Taylor | Administrative changes |

Distribution Record

| Date | Name | Department | Received |
|------|------|------------|----------|
| | | | |